The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study

Media type: E-Article

Title: The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study

Contributor: Hall, Lewis A.; McKay, Siobhan C.; Halle-Smith, James; Soane, Joshua; Osei-Bordom, Daniel-Clement; Goodburn, Lesley; Magill, Laura; Pinkney, Thomas; Radhakrishna, Ganesh; Valle, Juan W.; Corrie, Pippa; Roberts, Keith J.; Goodburn, Lesley; Hughes, Terry; Perry, Rita; Walters, Michael; Acharya, Radhika; Binnersly, Thomas; Brown, Samuel J.; Everitt, Rebecca; Hargreaves, Oscar; Hodgson, Samuel; Parylo, Jacek; Perrett, Madeleine; [...]

Published: Springer Science and Business Media LLC, 2023

Language: English

DOI: 10.1038/s41416-023-02220-2

ISSN: 0007-0920; 1532-1827

Origination:

Footnote:

Description: Abstract Introduction CONTACT is a national multidisciplinary study assessing the impact of the COVID-19 pandemic upon diagnostic and treatment pathways among patients with pancreatic ductal adenocarcinoma (PDAC). Methods The treatment of consecutive patients with newly diagnosed PDAC from a pre-COVID-19 pandemic cohort (07/01/2019-03/03/2019) were compared to a cohort diagnosed during the first wave of the UK pandemic (‘COVID’ cohort, 16/03/2020-10/05/2020), with 12-month follow-up. Results Among 984 patients (pre-COVID: n = 483, COVID: n = 501), the COVID cohort was less likely to receive staging investigations other than CT scanning (29.5% vs. 37.2%, p = 0.010). Among patients treated with curative intent, there was a reduction in the proportion of patients recommended surgery (54.5% vs. 76.6%, p = 0.001) and increase in the proportion recommended upfront chemotherapy (45.5% vs. 23.4%, p = 0.002). Among patients on a non-curative pathway, fewer patients were recommended (47.4% vs. 57.3%, p = 0.004) or received palliative anti-cancer therapy (20.5% vs. 26.5%, p = 0.045). Ultimately, fewer patients in the COVID cohort underwent surgical resection (6.4% vs. 9.3%, p = 0.036), whilst more patients received no anti-cancer treatment (69.3% vs. 59.2% p = 0.009). Despite these differences, there was no difference in median overall survival between the COVID and pre-COVID cohorts, (3.5 (IQR 2.8–4.1) vs. 4.4 (IQR 3.6–5.2) months, p = 0.093). Conclusion Pathways for patients with PDAC were significantly disrupted during the first wave of the COVID-19 pandemic, with fewer patients receiving standard treatments. However, no significant impact on survival was discerned.

Access State: Open Access

Search in field:

Recently searched for: